Click here to listen on Spotify There’s no question that over-prescribing of opioids kick-started the opioid crisis – the data is so overwhelming that nearly two dozen major companies have settled lawsuits to the tune of tens of billions of dollars because of that evidence. We’ve since dramatically cut the
The article below is quoted from “UT Works with Community Partners to Address Health Issues in Rural Counties and Underserved Groups,” published on UT’s Research, Innovation & Economic Development website on August 28th, 2024. Please see the full article to learn about other ways in which UT is helping to
Watch this documentary on the stigma of substance use during pregnancy, masterfully produced by ETSU’s Dr. Kelly Moore, funded by the Tennessee Department of Health. Featured are mothers in recovery and several experts across the state, including SMART Executive Director Dr. Jennifer Tourville and friends of SMART Dr. Stephen Loyd,
Click here to listen on Spotify There have been huge changes at the federal level regarding the prescribing of medications for opioid use disorder, particularly regarding buprenorphine. For two decades since the DATA 2000 law, addiction clinicians had to get a specialized waiver through the DEA to prescribe buprenorphine, and
If you’ve been listening to this podcast for a while, you know that there is strong evidence for the effectiveness of addiction treatment, and that the biggest obstacle we face in combating the overdose crisis is an overall lack of access to that treatment. Health insurance is of course a
Starting with the multiple guilty pleas from Purdue Pharma in 2020, thousands of lawsuits across the country have lead to a series of settlements from numerous pharmaceutical manufacturers and distributors for their role in the opioid crisis. From just the first and second wave of settlements with Cardinal Health, Janssen,
Purdue Pharma. Johnson and Johnson. CVS. Walgreens. I could keep going. Drug manufacturers and distributors have rightly come under scrutiny in light of the opioid abatement settlements. As these companies start paying hundreds of millions of dollars out across the country, in an effort to try to make up for
SMART has made available a fact sheet on Xylazine, highlighting all the information we currently know on this drug, including trends, presentations, treatment, and more. Please download and share! Download PDF | Full Text
At the end of 2022, the CDC released new prescribing guideline for opioids, replacing their last set from 2016. Excluding patients with cancer and other terminal illnesses, this guideline strongly emphasizes alternatives to opioids and urges extreme caution for physicians considering new opioid prescriptions, while also recommending how to appropriately
Emergent BioSolutions Inc. has announced that the FDA has fast-tracked their application for an over-the-counter (OTC) version of their trademarked Narcan nasal spray, and are anticipating approval as early as March 29th, 2023. A week prior, FDA Commissioner Robert Califf issued an open call for such applications, promising to assign
